1. [CASE 1 — QUESTION 1] A 55-year-old software engineer is referred to a movement disorders clinic after a 6-month history of resting tremor in the right hand, mild right-sided bradykinesia, and reduced arm swing. Examination confirms idiopathic Parkinson's disease. He has no cognitive complaints, works full time, and drives. His wife notes no behavioral changes. He asks directly: "My colleague told me I should avoid levodopa as long as possible because it damages the remaining dopamine cells. Is that true, and what should I start on?" His neurologist reviews the evidence base and the current treatment options, explaining both the neurotoxicity concern and the age-based rationale for initial therapy selection. Which of the following best represents the evidence-based response to his question about levodopa neurotoxicity and the pharmacological rationale for the recommended initial therapy in a patient of his age?

• A) His colleague's concern is fully supported by clinical evidence — the ELLDOPA trial demonstrated dose-dependent acceleration of dopaminergic neurodegeneration at all tested levodopa doses, confirmed by post-washout UPDRS deterioration in the highest-dose group; levodopa should be deferred indefinitely in patients under 60, and pramipexole should be started only when symptoms become severe enough to threaten employment.
• B) The neurotoxicity concern is not supported by clinical evidence — the ELLDOPA trial, which randomized patients to three levodopa dose levels or placebo for 40 weeks followed by a 2-week washout, found that all levodopa groups performed better than placebo at the post-washout assessment, with no evidence of accelerated neurodegeneration at any dose; levodopa should be initiated when motor symptoms are functionally impairing; however, at age 55, with a potentially 20 to 30 year treatment horizon, initiating a dopamine agonist (such as pramipexole or ropinirole) as first-line therapy is pharmacologically justified because agonists have a lower intrinsic propensity than levodopa to induce the striatal maladaptive plasticity underlying dyskinesia, and deferring or reducing cumulative levodopa exposure may reduce lifetime dyskinesia burden — accepting the trade-offs of inferior motor control and agonist-specific side effects including impulse control disorders.
• C) The neurotoxicity concern is valid based on the DATATOP trial, which demonstrated that levodopa at doses above 300 mg daily significantly accelerated striatal DAT loss compared with placebo at 5-year follow-up as measured by SPECT imaging, establishing the current maximum levodopa dose guideline of 300 mg daily in patients diagnosed before age 60; at his age, carbidopa/levodopa 10/100 mg twice daily is the maximum safe starting dose.
• D) The neurotoxicity concern is not applicable because this patient is over 50, and the neurodegeneration risk from levodopa is confined to patients diagnosed before age 40; for patients 50 to 65, standard carbidopa/levodopa initiation at 25/100 mg three times daily is the evidence-based first-line choice regardless of the dyskinesia risk differential between levodopa and agonists, because the risk of impulse control disorders from agonists in this age group outweighs any dyskinesia benefit.
• E) The neurotoxicity concern is unresolved and both levodopa and dopamine agonists should be deferred until the patient's DaT-SPECT scan confirms striatal dopamine transporter loss exceeding 40% of baseline, at which point the remaining terminal density is insufficient for the presynaptic buffering capacity that protects against dyskinesia, making levodopa safer to introduce because the buffer is already gone.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. The neurologist initiates pramipexole 0.375 mg three times daily with a gradual titration plan. The patient tolerates the medication and achieves reasonable tremor control at 1.5 mg three times daily over 8 weeks. At a follow-up visit, he mentions that he has started taking a daily multivitamin containing 25 mg pyridoxine (vitamin B6) on advice from a health website promoting B6 for nerve health in neurological conditions. He remains on pramipexole only, with no levodopa in his regimen. His neurologist reassures him but notes this would have been a significant concern under different circumstances. Which of the following best explains the specific clinical context in which pyridoxine supplementation at 25 mg daily poses a pharmacokinetic risk in Parkinson's disease management, and why that risk does not apply to this patient's current regimen?

• A) Pyridoxine at 25 mg daily poses a risk in any Parkinson's disease patient regardless of which dopaminergic agent they are taking because pyridoxine is a cofactor for dopamine beta-hydroxylase, the enzyme that converts dopamine to norepinephrine in sympathetic terminals; in patients on any dopaminergic therapy, excess pyridoxine accelerates dopamine-to-norepinephrine conversion, reducing striatal dopamine levels and worsening motor control; pramipexole avoids this risk because it is a direct receptor agonist that does not require dopamine as an intermediary.
• B) Pyridoxine at 25 mg daily inhibits COMT throughout peripheral tissues by competing with S-adenosylmethionine at the COMT active site; in levodopa-treated patients this increases the O-methylation of levodopa to 3-OMD, reducing levodopa bioavailability; pramipexole is unaffected because it is not a COMT substrate.
• C) Pyridoxine at 25 mg daily increases the expression of LAT1 transporters in the intestinal epithelium through a vitamin B6-responsive transcription factor, paradoxically increasing large neutral amino acid absorption and exacerbating the competition with levodopa at the absorption site; pramipexole is unaffected because it is not absorbed via LAT1.
• D) Pyridoxine at pharmacological doses above approximately 5 mg daily provides excess pyridoxal-5'-phosphate cofactor that upregulates peripheral aromatic amino acid decarboxylase (AADC) activity in the gut wall and systemic circulation, accelerating the conversion of levodopa to dopamine before it can cross the blood-brain barrier and substantially reducing CNS levodopa delivery; this risk applies specifically to patients taking levodopa without adequate carbidopa co-administration — or historically, to patients on levodopa monotherapy — because carbidopa, when present at adequate daily doses, irreversibly inhibits peripheral AADC regardless of cofactor availability and blocks the pyridoxine effect entirely; this patient is currently on pramipexole without any levodopa, so there is no levodopa substrate for peripheral AADC to convert, and the pyridoxine supplementation carries no pharmacokinetic risk to his current therapy.
• E) Pyridoxine at 25 mg daily competes with pramipexole for renal tubular secretion via organic cation transporters, reducing pramipexole clearance and raising plasma pramipexole concentrations by approximately 35%; in patients on pramipexole, this accumulation causes somnolence and orthostatic hypotension; the risk does not apply when carbidopa is co-administered because carbidopa inhibits renal OCT2, normalizing pramipexole clearance.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. Fourteen months after starting pramipexole, his wife calls the clinic in distress. She has discovered that over the past 5 months her husband has been spending approximately $3,000 monthly on online poker and sports betting, has accumulated $18,000 in credit card debt, and has been concealing this from her. When confronted, he minimizes the problem and says he "just enjoys the strategy." He has had no change in motor function on pramipexole 1.5 mg three times daily. His neurologist recognizes this as a medication-related complication and discusses management. Which of the following best explains the pharmacological mechanism of this complication, its relationship to the specific receptor pharmacology of pramipexole compared with levodopa, and the management approach?

• A) This is a dopamine agonist-induced impulse control disorder (ICD) occurring in approximately 15 to 17% of patients on dopamine agonists; the mechanism involves preferential stimulation of D3 receptors in the mesolimbic ventral striatum and nucleus accumbens by pramipexole, which has high D3 receptor affinity relative to levodopa-derived dopamine — D3 receptor-rich mesolimbic circuits govern reward processing, motivation, and hedonic learning, and tonic D3 stimulation lowers the threshold for reward-seeking behavior and impairs behavioral inhibition; a characteristic clinical feature is patient insight deficit, as demonstrated by this patient's minimization; management requires reducing or discontinuing pramipexole, transitioning motor control to carbidopa/levodopa, and counseling the patient and family that the behavior is pharmacologically induced and should improve with agonist reduction — though financial and relationship damage may require additional support.
• B) This is dopamine dysregulation syndrome — a condition in which the patient compulsively self-escalates pramipexole doses to achieve euphoria — and is caused by MAO-B-mediated conversion of pramipexole to an amphetamine-like metabolite in the striatum; management is immediate pramipexole discontinuation and inpatient detoxification followed by reintroduction at the starting dose under supervised daily dispensing.
• C) The gambling behavior represents a serotonin syndrome variant caused by pramipexole's partial agonist activity at 5-HT1A receptors in the nucleus accumbens, which disinhibits mesolimbic dopamine release via presynaptic autoreceptor activation; management is adding buspirone as a full 5-HT1A agonist to competitively displace pramipexole from these receptors and normalize mesolimbic tone without discontinuing pramipexole.
• D) The gambling behavior is a direct effect of pramipexole's D1 receptor agonism in the orbitofrontal cortex impairing executive inhibition of reward-seeking behavior; because D1 receptors are the dominant receptor subtype in the prefrontal cortex and pramipexole has higher D1 than D2 affinity, reducing the pramipexole dose to 0.75 mg three times daily (half the current dose) will reduce orbitofrontal D1 stimulation below the threshold for behavioral disinhibition while maintaining adequate D2-mediated motor benefit.
• E) The gambling is not a pharmacological effect — it represents pre-existing problem gambling that has been unmasked by the social disinhibition from dopaminergic therapy generally; the neurologist should refer the patient for cognitive behavioral therapy for gambling disorder and continue pramipexole unchanged, as there is no pharmacological basis for a relationship between dopamine agonist dose and gambling behavior.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. The neurologist reduces pramipexole over 4 weeks and initiates carbidopa/levodopa 25/100 mg three times daily. The patient's gambling behavior resolves within 6 weeks of agonist discontinuation. Motor control on carbidopa/levodopa is excellent — better than on pramipexole — but he expresses concern about starting levodopa at age 56, asking whether the dyskinesia he has "heard about" will now develop faster because he is on levodopa earlier than planned. The neurologist addresses this directly. Which of the following most accurately characterizes the relationship between age at levodopa initiation, cumulative levodopa exposure, and dyskinesia risk, and provides the most complete honest answer to his concern?

• A) His concern is unfounded because dyskinesia is exclusively a function of total daily levodopa dose — not duration of exposure or age at initiation; as long as his total daily levodopa dose remains below 600 mg, dyskinesia risk is negligible regardless of how many years he takes it; the agonist-first strategy was intended solely to delay the onset of wearing-off, not to prevent dyskinesia.
• B) His concern is partially valid but overstated; dyskinesia risk is primarily genetic, determined by CYP2D6 metabolizer status and COMT Val158Met genotype; patients who are CYP2D6 poor metabolizers and COMT Val/Val homozygotes develop dyskinesia regardless of when levodopa is started or what dose they take; genetic testing should be offered before committing to a long-term levodopa regimen.
• C) His concern is fully warranted and the switch to levodopa at age 56 has permanently forfeited the dyskinesia protection that agonist-first therapy was designed to provide; the published data show that any levodopa exposure before age 60 produces dyskinesia in over 80% of patients within 3 years regardless of dose, because the neuroplastic capacity of the striatum at this age makes sensitization almost universal; the only remaining option to prevent dyskinesia is prophylactic DBS surgery within 2 years.
• D) His concern is not clinically relevant because the ICD that required agonist discontinuation has reset his dyskinesia risk profile; the dopamine receptor sensitization that underlies ICD is the same process that underlies dyskinesia, and patients who develop ICD on agonist therapy have already undergone the mesolimbic sensitization that dyskinesia requires; switching to levodopa will not produce additional sensitization beyond what the ICD itself has already induced.
• E) His concern deserves an honest answer: dyskinesia risk does accumulate with levodopa exposure duration and is higher in younger patients at equivalent exposure — approximately 30% at 3 years, over 50% at 5 years, and approaching 90% at 10 years of levodopa treatment in most series, with younger age at onset associated with faster sensitization due to greater striatal neuroplasticity; the agonist-first strategy was intended to reduce and delay cumulative levodopa exposure, and the ICD that forced the switch is a genuine pharmacological setback to that goal; however, the dyskinesia risk would have accumulated eventually regardless, carbidopa/levodopa provides better motor control than pramipexole did, and when dyskinesia does develop it can be managed — dose reduction, extended-release amantadine, LCIG, or DBS — so the decision to switch was correct and the appropriate response is honest disclosure of the risk with a management plan rather than false reassurance.

5. [CASE 2 — QUESTION 1] A 69-year-old retired schoolteacher with an 8-year history of Parkinson's disease presents to the movement disorders clinic reporting a consistent and frustrating pattern: her morning dose of carbidopa/levodopa 25/100 mg (taken at 7 AM before breakfast) works well, her 11 AM dose (taken 20 minutes before lunch containing grilled salmon, lentils, and a protein shake) consistently fails, and her 3 PM dose (taken before a light fruit and vegetable snack) works reasonably well. She describes the 11 AM failure as "the levodopa just not switching on." Her MoCA is 28/30, her carbidopa total daily dose is 100 mg (4 × 25 mg), and she has no gastroparesis symptoms. Which of the following best explains the mechanistic basis for the meal-specific failure of her 11 AM levodopa dose?

• A) The 11 AM dose fails because gastric acid secretion peaks at midday in response to the anticipation of a large meal, chemically degrading levodopa in the stomach before it can be emptied into the small intestine; the alkaline protein shake compounds this by raising gastric pH above 7.5, causing levodopa to precipitate as an insoluble basic salt; the morning dose succeeds because fasting gastric acid levels are lower and more stable.
• B) The 11 AM failure reflects carbidopa dose stacking — her total daily carbidopa of 100 mg provides adequate peripheral AADC inhibition when distributed evenly across doses, but taking a dose 20 minutes before a large meal accelerates carbidopa absorption and produces a transient plasma carbidopa peak that paradoxically inhibits central AADC through a transient BBB breach caused by the meal-related mesenteric blood flow surge, reducing striatal dopamine synthesis from levodopa.
• C) Digestion of the protein-rich midday meal releases large neutral amino acids — including phenylalanine, leucine, isoleucine, valine, and tryptophan — into the proximal small intestinal lumen simultaneously with her levodopa dose; these amino acids compete with levodopa for LAT1 (large neutral amino acid transporter 1)-mediated absorption at the intestinal epithelium, reducing the fraction of levodopa absorbed; the absorbed dietary amino acids then circulate in plasma and compete with levodopa at LAT1 again at the blood-brain barrier, reducing CNS levodopa entry independently of plasma levodopa levels; the morning dose succeeds because fasting conditions provide minimal competition at both sites, and the afternoon dose works better because a fruit and vegetable snack provides minimal protein and therefore minimal amino acid competition.
• D) The protein-rich meal stimulates release of glucagon-like peptide-1 (GLP-1) from duodenal L cells, which activates GLP-1 receptors on the blood-brain barrier endothelium and transiently downregulates LAT1 expression at the BBB; this GLP-1-mediated suppression of BBB LAT1 specifically impairs levodopa CNS entry during the postprandial period regardless of how much levodopa was absorbed from the intestine.
• E) The 11 AM failure is a wearing-off phenomenon unrelated to the meal — by 11 AM, the patient has been awake for 4 hours and her levodopa has worn off from the 7 AM dose; the meal timing is coincidental; the correct management is shortening the dosing interval from 4 hours to 3 hours rather than any dietary modification.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. Her neurologist advises her to take all levodopa doses at least 40 minutes before meals and to redistribute her protein intake to the evening meal. She follows this consistently and her morning and afternoon doses improve substantially. However, 3 months later she returns reporting that her midday dose is still inconsistent even when she takes it well before eating — some days it works, some days it does not — and the problem is worse in the afternoon than in the morning despite the afternoon dose also being taken before a low-protein snack. A plasma 3-O-methyldopa (3-OMD) level drawn at 3 PM is 7.9 micromol/L (reference range less than 2.0 micromol/L). The neurologist explains that 3-OMD accumulation is contributing an additional, pharmacologically distinct form of LAT1 competition that is not addressed by meal timing alone. Which of the following best explains why 3-OMD accumulation worsens through the day despite adequate dietary protein management, and how entacapone addresses this specific problem?

• A) 3-OMD is a large neutral amino acid produced by peripheral COMT-mediated O-methylation of levodopa; it has a plasma half-life of approximately 15 hours — far longer than levodopa's 1 to 3 hours — meaning it accumulates across multiple levodopa doses throughout the day, reaching its highest steady-state plasma concentration in the afternoon after the morning and midday doses have each contributed to its production; at high plasma concentrations, 3-OMD competes with levodopa at LAT1 for both intestinal absorption and BBB transport, creating a pharmacologically generated competitive burden that is independent of dietary protein and worsens predictably through the day; entacapone, by inhibiting peripheral COMT at each dose, reduces 3-OMD production, lowers its steady-state plasma concentration, and relieves this controllable component of the LAT1 competitive load — additionally extending levodopa's effective plasma half-life by preserving levodopa from O-methylation.
• B) 3-OMD accumulates because the patient's renal function has declined with age, and at her creatinine clearance of approximately 45 mL/min, 3-OMD clearance is reduced by approximately 60% compared with a patient with normal renal function; the afternoon rise in 3-OMD reflects diurnal variation in renal blood flow; entacapone reduces 3-OMD production but also directly enhances renal 3-OMD clearance by inhibiting its tubular reabsorption via OAT1.
• C) 3-OMD accumulates because carbidopa at 25 mg per dose is insufficient to fully inhibit peripheral AADC, leaving residual AADC activity that converts levodopa to dopamine; dopamine is then O-methylated by COMT to 3-methoxytyramine, which is erroneously measured as 3-OMD by the laboratory assay; entacapone reduces the apparent 3-OMD level by inhibiting COMT-mediated 3-methoxytyramine production.
• D) 3-OMD accumulates because COMT activity has an endogenous diurnal rhythm driven by cortisol, with peak COMT activity in the afternoon hours coinciding with the cortisol nadir; the afternoon timing of the elevated measurement reflects this circadian COMT upregulation; entacapone provides uniform COMT inhibition throughout the day, eliminating the afternoon COMT activity peak and preventing the diurnal 3-OMD accumulation.
• E) 3-OMD accumulates because the patient's carbidopa doses are being taken too close together, producing a sustained carbidopa plasma concentration that paradoxically activates a feedback upregulation of COMT expression in peripheral tissues; this compensatory COMT upregulation converts an increasing fraction of each levodopa dose to 3-OMD; entacapone bypasses this feedback loop by inhibiting COMT directly without contributing to the carbidopa-mediated upregulation signal.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. Entacapone 200 mg is added to each of her four daily carbidopa/levodopa doses. Her motor control improves substantially over the following 6 weeks and her 3-OMD level drops to 1.4 micromol/L on repeat testing. At the same visit, her anticoagulation clinic contacts the movement disorders team: she has been on warfarin for atrial fibrillation with a stable INR of 2.3 for 14 months, but her INR measured this week is 3.9. She has had no dietary changes, no new medications from other providers, and no missed warfarin doses. Which of the following best identifies the mechanism of the INR elevation and the appropriate management response?

• A) Entacapone displaces warfarin from plasma albumin binding by occupying the same high-affinity binding sites, increasing the free warfarin fraction from approximately 1% to approximately 4% and tripling the pharmacodynamically active plasma concentration; management is reducing warfarin by 50% and rechecking INR in 3 days; if INR normalizes, the reduced warfarin dose should be maintained permanently because the displacement interaction is sustained as long as entacapone is continued.
• B) Entacapone inhibits intestinal P-glycoprotein, increasing warfarin absorption from approximately 80% to nearly 100% and raising plasma warfarin AUC by approximately 25%; the management is reducing warfarin by 20% to compensate for the increased bioavailability; no additional INR monitoring beyond the standard monthly check is required because the P-glycoprotein interaction reaches a new stable state within 2 weeks.
• C) The INR elevation is caused by entacapone's inhibition of vitamin K epoxide reductase (VKOR) — the same enzyme target as warfarin — producing an additive anticoagulant effect; management is discontinuing entacapone because its direct VKOR inhibition precludes safe co-administration with warfarin at any dose; tolcapone should be used instead as it does not inhibit VKOR.
• D) The INR elevation is coincidental and unrelated to entacapone; entacapone has no pharmacokinetic or pharmacodynamic interactions with warfarin documented in its prescribing information; the most likely explanation is that the patient has been consuming extra portions of vitamin K-rich foods that temporarily elevated her INR by an unknown mechanism; warfarin dose should be unchanged and INR rechecked in 2 weeks.
• E) Entacapone inhibits CYP2C9, the principal hepatic enzyme responsible for S-warfarin hydroxylation and clearance; by reducing S-warfarin metabolism, entacapone raises plasma S-warfarin concentrations and prolongs its anticoagulant effect, raising the INR; this interaction is documented in the entacapone prescribing information, which specifically recommends monitoring INR when entacapone is added to or withdrawn from a regimen that includes warfarin; management is reducing the warfarin dose to bring the INR back to therapeutic range, performing more frequent INR monitoring (e.g., weekly) until the INR restabilizes, and continuing entacapone given the significant motor benefit it is providing.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. The warfarin dose is adjusted and the INR restabilizes at 2.5 over the following month with weekly then biweekly monitoring. Her entacapone is continued. Six months later, her primary care physician, managing a medication refill during a gap in neurology follow-up, switches her from carbidopa/levodopa IR 25/100 mg four times daily plus entacapone to carbidopa/levodopa CR 50/200 mg twice daily (without entacapone), reasoning that the twice-daily CR regimen is simpler and the higher per-dose levodopa content compensates for the lost entacapone. She returns to the movement disorders clinic 3 weeks later with significant wearing-off, averaging 4 hours of additional off time per day compared with her prior regimen. Which of the following best identifies the two pharmacokinetic errors in the primary care physician's reasoning and explains why the switch produced worse motor control despite the nominally higher levodopa per dose?

• A) The first error was discontinuing entacapone, which provided AADC inhibition augmentation; without entacapone's AADC-inhibiting effect, more levodopa is now converted to dopamine peripherally, reducing CNS delivery; the second error was using the CR formulation, which has a higher carbidopa-to-levodopa ratio (1:4) than the IR formulation (also 1:4) but releases carbidopa faster than levodopa due to differential matrix solubility, producing a window of excess carbidopa that paradoxically inhibits CNS AADC and reduces dopamine synthesis from the levodopa that does reach the brain.
• B) The first error was assuming bioavailability equivalence between CR and IR formulations at the same total daily levodopa dose — CR carbidopa/levodopa has approximately 70 to 75% of the oral bioavailability of IR, so 400 mg CR per day provides only approximately 280 to 300 mg effective levodopa exposure compared with the 400 mg she was receiving from IR; the second error was discontinuing entacapone, which had been extending each levodopa dose's effective plasma half-life by inhibiting COMT-mediated conversion to 3-OMD and reducing her 3-OMD competitive burden at LAT1 — without entacapone, 3-OMD will re-accumulate, worsening LAT1 competition and amplifying the already-reduced levodopa bioavailability from the CR switch; the combined effect of reduced CR bioavailability and loss of entacapone produces a substantially lower effective levodopa delivery than the prior regimen.
• C) The first error was reducing dosing frequency from four to twice daily — the 12-hour interdose interval substantially exceeds levodopa's plasma half-life of 1 to 3 hours, producing complete levodopa washout for 9 to 10 hours daily; the second error was that CR 50/200 mg tablets require gastric acid for dissolution and this patient's proton pump inhibitor (which she was taking) raises gastric pH above 6.0 and prevents CR matrix dissolution, so the CR formulation is producing essentially zero levodopa delivery in this patient.
• D) The first error was using twice-daily dosing, which concentrates levodopa delivery into two large pulses per day; the pulsatile stimulation from twice-daily dosing is more dyskinesiogenic than four-times-daily dosing and will induce early peak-dose dyskinesia that manifests clinically as wearing-off because the patient is misinterpreting dyskinesia-free periods as off states; the second error was discontinuing entacapone, which suppressed the pulsatile stimulation inherent in four-times-daily dosing; without entacapone's smoothing effect, the twice-daily pattern will produce dyskinesia, not wearing-off.
• E) The first error was that CR formulations should never be used in patients on entacapone because the COMT inhibition by entacapone interacts with the polymer matrix of CR tablets, accelerating matrix dissolution and converting CR to an immediate-release pharmacokinetic profile; the second error was that discontinuing entacapone in a patient with chronic COMT inhibition causes acute COMT upregulation rebound, producing excess 3-OMD far above baseline and causing severe LAT1 blockade for 3 to 4 weeks.

9. [CASE 3 — QUESTION 1] A 72-year-old retired physician with a 13-year history of Parkinson's disease is seen in the movement disorders clinic. He has been on carbidopa/levodopa for 11 years and has developed progressive wearing-off over the past 18 months. He takes carbidopa/levodopa 25/100 mg five times daily with entacapone at each dose and rasagiline 1 mg daily. He reports that 9 years ago, on the same total daily levodopa dose of 500 mg, he had no motor fluctuations; now, on an identical dose, he has 3 to 4 hours of off time daily. He asks his former colleague, the neurologist, to explain why the same drug at the same dose now produces fluctuations when it did not 9 years ago. Which of the following best explains the mechanism underlying the progressive emergence of wearing-off with advancing Parkinson's disease at an unchanged levodopa dose?

• A) Wearing-off emerges because peripheral AADC becomes progressively less efficient with age and disease duration, converting a smaller fraction of each levodopa dose to dopamine in the peripheral circulation; carbidopa therefore has progressively less peripheral dopamine to suppress, reducing the protective buffering of the area postrema and paradoxically increasing motor receptor exposure to pharmacologically inadequate dopamine concentrations.
• B) Wearing-off emerges because the blood-brain barrier LAT1 transporter progressively downregulates its expression with advancing PD through a mechanism involving alpha-synuclein accumulation at the BBB endothelium, reducing the fraction of each levodopa dose entering the CNS as disease advances; the identical plasma levodopa levels now translate to lower CNS levodopa delivery than they did 9 years ago.
• C) Wearing-off emerges because of progressive upregulation of central AADC in non-dopaminergic cells as disease advances; the upregulated AADC converts levodopa to dopamine faster and in larger quantities than normal, paradoxically creating a higher peak with a steeper fall — the rapid dopamine production in non-dopaminergic cells that cannot store it vesicularly produces a sharp peak followed by rapid diffuse release, shortening the effective duration of each dose.
• D) Wearing-off emerges because surviving nigrostriatal dopaminergic terminals — which previously converted levodopa to dopamine, stored it in synaptic vesicles, and released it tonically in a regulated fashion that buffered the pulsatile pharmacokinetics of oral levodopa into stable striatal dopamine concentrations — are progressively lost with advancing disease; as terminal density falls, the presynaptic buffering capacity is depleted; dopamine produced from levodopa in residual neurons and non-dopaminergic cells cannot be vesicularly stored and is instead released diffusely in proportion to instantaneous plasma levodopa concentration; striatal dopamine availability now mirrors the short half-life pharmacokinetic profile of plasma levodopa directly, converting the 1 to 3 hour plasma half-life into corresponding motor fluctuations that were not present when sufficient buffering capacity existed.
• E) Wearing-off emerges because long-term levodopa exposure causes progressive upregulation of MAO-B in the striatum, increasing the rate of dopamine catabolism to DOPAC; the same amount of dopamine produced from each levodopa dose is now metabolized faster at the synaptic level, shortening the duration of D2 receptor occupancy; this is why rasagiline was added — it directly counteracts the upregulated MAO-B — but cannot fully compensate because MAO-B upregulation exceeds what rasagiline can inhibit at standard doses.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. Over the next 6 months his wearing-off progresses despite shortening the dosing interval to every 3 hours, increasing entacapone dosing, and adding extended-release amantadine for emerging peak-dose dyskinesia. His total daily levodopa is now 700 mg in 7 divided doses. He still averages 4 hours of off time daily and his off episodes are becoming less predictable and less responsive to his scheduled doses. A gastric emptying study is performed as part of the evaluation for on-off fluctuations and reveals markedly delayed gastric emptying with 78% of solids retained at 2 hours (normal less than 60%). The neurologist explains that the gastroparesis fundamentally changes what oral pharmacological strategies can achieve. Which of the following best explains why gastroparesis creates a therapeutic ceiling for oral levodopa optimization that cannot be overcome by any adjustment to oral dose, frequency, formulation, or adjunctive agents?

• A) Gastroparesis reduces intestinal blood flow by causing mesenteric venous congestion from chronic gastric distension, reducing the delivery of absorbed levodopa from the mesenteric capillaries to the systemic circulation; all oral optimization strategies increase the amount of levodopa that reaches the intestinal lumen but cannot increase mesenteric blood flow in the presence of gastroparesis-related venous congestion.
• B) All oral levodopa pharmacokinetic strategies — adjusting dose size, dosing frequency, formulation type (IR, CR, extended-release), and adjunctive agents (COMT inhibitors, MAO-B inhibitors) — act downstream of the gastric emptying step; they optimize what happens to levodopa after it reaches the proximal small intestine, but cannot act on levodopa that remains trapped in the stomach, where it cannot be absorbed and cannot exert any therapeutic effect; with 78% of gastric contents retained at 2 hours, the majority of each levodopa dose remains in the stomach for an unpredictable duration, and regardless of the dose size, frequency, formulation, or adjunct chosen, the levodopa in the stomach cannot be absorbed until gastric emptying occurs — converting all oral strategies from a pharmacokinetic problem into a delivery problem that pharmacokinetic solutions cannot address.
• C) Gastroparesis causes bacterial overgrowth in the stomach, and the overgrown bacteria express high levels of AADC that convert levodopa to dopamine in the gastric lumen before absorption can occur; because carbidopa does not reach adequate concentrations in the gastric lumen (it is rapidly absorbed in the proximal duodenum before the levodopa can be converted), the bacterial AADC is unprotected; all oral formulations deliver levodopa into this bacterial conversion environment, and no dose or frequency adjustment can overcome bacterial conversion.
• D) Gastroparesis impairs the dissolution of carbidopa/levodopa tablets by reducing gastric acid secretion due to vagal neuropathy; without adequate acid, the carbidopa/levodopa tablet matrix does not dissolve and the tablet passes intact into the small intestine, where it is excreted rather than absorbed; liquid carbidopa/levodopa formulations would overcome this problem but are not commercially available in the required concentration.
• E) Gastroparesis causes periodic retrograde flow of partially digested small intestinal contents back into the stomach, including previously absorbed levodopa that re-enters the stomach as dopamine rather than levodopa; this retrograde dopamine is reabsorbed from the stomach and stimulates the area postrema, causing nausea that further inhibits gastric motility and worsens the gastroparesis in a positive feedback loop; COMT inhibitors worsen this cycle by increasing the fraction of levodopa converted to dopamine available for retrograde flow.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. The neurologist refers him for LCIG evaluation. He is a good candidate — intact cognition, good levodopa responsiveness when he does achieve an on state, adequate social support, and motivation for the procedure. After PEG-J tube placement, LCIG is started with an individualized morning dose and maintenance rate. Over the following 4 weeks his off time decreases from 4 hours to less than 30 minutes daily and his dyskinesia, while initially worse, is manageable with amantadine. He asks the neurologist to explain exactly what the LCIG infusion is doing differently from oral levodopa that produces this improvement. Which of the following most accurately explains the pharmacokinetic mechanism by which LCIG reduces off time compared with optimized oral therapy, and describes the pharmacodynamic consequence of converting pulsatile to continuous levodopa delivery?

• A) LCIG improves motor control primarily by providing a higher total daily levodopa dose than was achievable orally; the jejunal route allows dose escalation beyond the 700 mg oral ceiling because jejunal AADC activity is lower than gastric AADC activity, converting a smaller fraction of the delivered dose to dopamine before absorption; the higher effective levodopa dose overwhelms the LAT1 competition from dietary amino acids that was limiting oral therapy.
• B) LCIG works by delivering carbidopa and levodopa simultaneously at a fixed ratio directly to the systemic circulation via mesenteric capillary absorption, completely bypassing first-pass hepatic metabolism; the elimination of hepatic first-pass conversion to 3-OMD and DOPAC is the primary pharmacokinetic mechanism, and it produces a 3- to 4-fold increase in levodopa bioavailability compared with oral dosing.
• C) LCIG delivers carbidopa/levodopa gel continuously into the proximal jejunum via PEG-J tube, bypassing the gastric emptying step that was the primary source of pharmacokinetic variability in this patient; continuous jejunal delivery provides a steady, sustained supply of levodopa to the LAT1 absorption site throughout the 16-hour infusion day, converting the sharp peaks and troughs of oral pulsatile delivery into a stable, near-continuous plasma levodopa concentration; this stable plasma profile is transmitted to the striatum — where presynaptic buffering capacity is depleted — as correspondingly stable striatal dopamine availability, eliminating the plasma levodopa troughs that produced the wearing-off and reducing the magnitude of peaks that produced dyskinesia; the 4-hour reduction in off time observed in the pivotal LCIG trial reflects this pharmacokinetic normalization.
• D) LCIG improves motor control because the jejunal gel formulation contains a proprietary levodopa polymorph with a 5-fold higher affinity for LAT1 than the oral tablet formulation; this higher LAT1 affinity ensures competitive priority over dietary amino acids at the BBB, so even when plasma amino acid concentrations are elevated after protein-containing meals the jejunal levodopa polymorph is preferentially transported into the CNS.
• E) LCIG achieves continuous motor benefit because the PEG-J tube delivers levodopa directly into the portal vein via the jejunal submucosa, bypassing the LAT1 absorption step entirely and delivering levodopa directly to the hepatic circulation where it is immediately distributed to the brain via the hepatic vein and inferior vena cava; this direct portal delivery produces brain levodopa concentrations 8 to 10 times higher than oral dosing at equivalent doses.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. Seven months after LCIG initiation, with motor control remaining excellent, his wife calls the clinic at 9 AM on a weekday reporting that her husband woke at his usual 6 AM, connected the morning cassette, and started the infusion as normal. By 7:30 AM, however, he was severely off — unable to rise from his chair, with generalized rigidity and barely audible speech — which is completely unlike his usual early morning state since LCIG was started. The pump display shows normal operation, the cassette level is decreasing at the expected rate, and external tubing is intact and patent. She has given him two oral carbidopa/levodopa rescue tablets but he has not responded after 45 minutes. Which of the following is the most likely explanation for this clinical picture and the appropriate immediate management?

• A) The most likely explanation is internal tube displacement — migration of the jejunal extension tube back through the pylorus into the stomach — which produces a clinical picture of complete loss of LCIG benefit despite normal external pump operation because the gel is being delivered into the stomach rather than the proximal jejunum; gastric delivery is subject to all the gastroparesis-related variability that LCIG was designed to eliminate, and in this patient with severe gastroparesis the gel is not being emptied into the jejunum; the oral rescue tablets have not responded because his gastroparesis also delays their absorption; the immediate management is urgent abdominal X-ray to confirm tube position, subcutaneous apomorphine injection to bypass all gastrointestinal absorption and rescue the off episode while imaging is arranged, and urgent endoscopic tube repositioning or replacement.
• B) The most likely explanation is LCIG pump battery failure producing complete cessation of gel delivery despite the pump display showing normal operation; pump display malfunction is a known failure mode of the LCIG system in which the display continues to show normal parameters while the motor has stopped; management is replacing the entire pump unit with a backup pump while the failed unit is sent for service evaluation.
• C) The most likely explanation is that the morning cassette was stored incorrectly — outside the required 2 to 8°C refrigerator temperature — overnight, causing levodopa degradation to inactive catechol metabolites; the cassette visually appears normal but contains pharmacologically inactive gel; management is replacing the cassette immediately with a properly refrigerated unit and restarting the infusion at 150% of the usual morning dose to compensate for the missed morning delivery.
• D) The most likely explanation is LCIG-induced peripheral neuropathy reaching a critical threshold overnight, with acute axonal failure in the corticospinal tract from carbidopa-mediated PLP depletion producing an upper motor neuron syndrome that resembles severe parkinsonism; management is immediately discontinuing LCIG and administering pyridoxine 100 mg IV to replenish PLP and restore axonal function.
• E) The most likely explanation is that the patient has developed acute tolerance to continuous dopaminergic stimulation — a recognized complication of 7 months of LCIG therapy in which D2 receptors undergo complete internalization and desensitization during continuous stimulation; the acute off reflects complete receptor downregulation that cannot be reversed by dose escalation; management is a supervised 48-hour LCIG holiday under hospital monitoring to allow receptor re-sensitization, followed by LCIG restart at 20% lower dose.

13. [CASE 4 — QUESTION 1] A 64-year-old woman with a 10-year history of Parkinson's disease presents to a movement disorders clinic reporting choreiform involuntary movements of her arms and trunk that appear approximately 45 to 60 minutes after each levodopa dose, persist for about 90 minutes, and then resolve as her dose wears off. She describes good motor function between the dyskinesia episodes. Her regimen is carbidopa/levodopa 25/100 mg five times daily with no adjunctive agents. Her MoCA is 28/30. Her neurologist describes the molecular basis of her dyskinesia to help her understand why this develops after years of levodopa therapy. Which of the following best describes the molecular mechanisms in striatal neurons that underlie levodopa-induced dyskinesia and explains why peak-dose dyskinesia occurs specifically at maximum levodopa effect rather than during wearing-off or the off state?

• A) Peak-dose dyskinesia occurs because peak plasma levodopa concentrations temporarily saturate the synaptic dopamine reuptake transporter (DAT) in residual nigrostriatal terminals, producing prolonged dopamine receptor occupancy that exceeds the threshold for choreiform movement generation; the dyskinesia-free off state occurs when DAT activity is restored as plasma levodopa falls; the molecular basis is DAT phosphorylation-dependent internalization triggered by high dopamine concentrations.
• B) Peak-dose dyskinesia occurs because levodopa at peak plasma concentrations is converted to dopamine quinones in non-dopaminergic striatal cells; the quinones bind covalently to postsynaptic D2 receptors, permanently activating them in a constitutively active conformation; the dyskinesia is progressive because more receptors are permanently activated with each dose; the dyskinesia-free wearing-off reflects the fraction of receptors not yet modified.
• C) Peak-dose dyskinesia occurs because peripheral dopamine produced from levodopa at peak plasma concentrations crosses the blood-brain barrier in significantly increased amounts at high plasma concentrations, stimulating cortical motor areas directly via a concentration-dependent BBB permeability increase; the direct cortical dopamine stimulation produces the choreiform movements, which resolve when plasma levodopa — and therefore peripheral dopamine — falls.
• D) Peak-dose dyskinesia reflects acute dopamine receptor overstimulation at every dose from the time levodopa is started; the long onset (years before dyskinesia develops) simply reflects the time required for the patient's inhibitory interneurons in the striatum to be depleted by the chronic dopaminergic overstimulation; once depleted, the lack of inhibitory interneuron modulation allows choreiform movements to manifest at each peak-dose period.
• E) Peak-dose dyskinesia reflects maladaptive neuroplasticity in direct pathway medium spiny neurons (MSNs) of the striatum induced by years of pulsatile, non-physiological dopaminergic stimulation: deltaFosB — a truncated, highly stable FosB isoform — accumulates in direct pathway MSNs with repeated dopaminergic activation, reprogramming gene expression to increase their excitability; concurrently, AMPA receptor subunit composition shifts toward calcium-permeable GluA1-containing receptors and NMDA receptor subunit GluN2B undergoes increased phosphorylation, collectively potentiating corticostriatal glutamatergic transmission at these synapses; at peak levodopa concentrations, this sensitized direct pathway circuitry is maximally activated by the dopamine surge, generating involuntary movement; during wearing-off and the off state, dopamine concentrations fall below the sensitization activation threshold and the choreiform movements cease, leaving the patient in the off state without dyskinesia.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. The neurologist initiates extended-release amantadine (Gocovri 274 mg at bedtime) to address the peak-dose dyskinesia. The patient asks why a medication taken at bedtime helps with movements that occur during the day, and whether taking it at bedtime means she will miss out on its effect for the first few hours after waking. Which of the following most accurately explains the pharmacokinetic rationale for bedtime dosing of extended-release amantadine and addresses her specific concern about morning coverage?

• A) Extended-release amantadine taken at bedtime is absorbed during sleep via a nocturnal gastric absorption window that is unique to the ER formulation; the ER matrix is specifically designed to dissolve only when gastric pH rises above 6.5, which occurs exclusively during sleep due to the circadian rhythm of acid secretion; peak absorption at 3 to 4 AM produces peak plasma concentrations precisely at waking, providing optimal anti-dyskinetic coverage from the first morning levodopa dose.
• B) Extended-release amantadine taken at bedtime exerts its anti-dyskinetic effect during the night by resetting NMDA receptor phosphorylation states during the sleep-related period of low dopamine stimulation; by morning, the NMDA receptors have been pharmacologically re-equilibrated to a less sensitized state; the plasma amantadine concentration at waking is actually at its lowest, but the overnight receptor reset provides daytime dyskinesia protection that persists for 18 to 24 hours independent of plasma concentration.
• C) Extended-release amantadine (Gocovri) has a delayed time to peak plasma concentration of approximately 7 to 8 hours after ingestion; taken at bedtime (approximately 10 PM), peak plasma concentrations are reached at approximately 5 to 6 AM, coinciding with the early waking period and the first morning levodopa dose — the period when dyskinesia risk is highest; this pharmacokinetic engineering delivers maximum anti-dyskinetic NMDA receptor antagonism precisely when it is most needed, while the lower plasma concentrations during earlier sleep hours reduce the risk of stimulant-like side effects (insomnia, agitation) that would occur if the peak coincided with the time of dosing; she will not miss the first-morning coverage because the peak is timed to arrive at waking.
• D) Extended-release amantadine taken at bedtime works exclusively through its dopamine-releasing properties rather than NMDA antagonism; the ER formulation slowly releases amantadine during sleep, which triggers dopamine release from residual nigrostriatal terminals during the overnight fasting period; the dopamine released overnight provides receptor priming that reduces the sensitization response to the first morning levodopa dose; the timing at bedtime is chosen to avoid the somnolence that dopamine-releasing agents produce when taken during waking hours.
• E) The bedtime dosing of extended-release amantadine is not pharmacokinetically motivated — it is chosen solely for patient convenience and to avoid the anticholinergic side effects of amantadine that occur when it is taken during waking hours; the plasma concentration at waking is identical whether the ER formulation is taken at bedtime or at 6 AM, because the ER matrix releases at a constant rate regardless of the time of day; the patient's concern about morning coverage is valid and she should take a supplemental immediate-release amantadine 100 mg tablet at waking to ensure adequate plasma concentrations for the first morning levodopa dose.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. Six months after starting extended-release amantadine, her peak-dose dyskinesia is substantially improved — reduced from 90 minutes to approximately 20 minutes of mild dyskinesia after each dose. However, she begins experiencing two to three unpredictable off episodes per week that are severe enough to leave her unable to ambulate and do not respond to an additional oral levodopa tablet taken at the onset of the episode. Her neurologist considers a rescue agent. She has moderate COPD with an FEV1 of 54% predicted and uses a tiotropium inhaler. When levodopa inhalation powder (Inbrija) is considered, her pulmonologist raises a contraindication. The neurologist then considers subcutaneous apomorphine. Which of the following correctly explains why inhaled levodopa is contraindicated in this patient and identifies the specific prescribing requirement and monitoring need for subcutaneous apomorphine initiation?

• A) Inhaled levodopa is contraindicated in COPD because the anticholinergic properties of the dry powder carrier particles antagonize tiotropium at bronchial M3 receptors, blocking tiotropium's bronchodilatory effect and precipitating acute bronchospasm; subcutaneous apomorphine requires no special initiation protocol and can be prescribed immediately with standard-dose titration beginning at 2 mg per injection.
• B) Inhaled levodopa carries a risk of bronchospasm in patients with underlying airway disease including COPD and asthma, and the FDA prescribing information requires spirometric evaluation before prescribing — this patient's FEV1 of 54% predicted represents significant airflow obstruction that substantially increases bronchospasm risk; subcutaneous apomorphine bypasses the pulmonary route entirely but requires domperidone antiemetic pretreatment (10 mg three times daily begun 3 days before the first apomorphine injection) because apomorphine is a potent dopamine agonist that produces intense nausea via area postrema D2 stimulation at initiation; metoclopramide is contraindicated as an antiemetic in this patient because it is a D2 antagonist that crosses the BBB and worsens parkinsonism; ondansetron co-administration with apomorphine is specifically contraindicated due to risk of clinically significant QTc prolongation.
• C) Inhaled levodopa is contraindicated in patients on tiotropium because levodopa and tiotropium compete for binding to the same airway M3 receptor, reducing tiotropium's bronchodilatory effect by approximately 60% and worsening baseline airflow obstruction; subcutaneous apomorphine is initiated at 6 mg per injection as the standard starting dose and requires no antiemetic pretreatment because the subcutaneous route bypasses the area postrema entirely and does not cause nausea.
• D) Inhaled levodopa is contraindicated in COPD because COPD patients express high levels of pulmonary AADC that convert the inhaled levodopa dose to dopamine in the alveolar epithelium before systemic absorption; the locally produced dopamine causes pulmonary vasoconstriction and hypoxemia; patients on carbidopa can use inhaled levodopa safely because carbidopa distributes to the lung and blocks pulmonary AADC; tiotropium has no interaction with inhaled levodopa.
• E) Inhaled levodopa is contraindicated in patients with COPD only if their FEV1 is below 30% predicted; at an FEV1 of 54% predicted this patient meets the spirometry threshold for safe inhaled levodopa use; the contraindication is the concurrent tiotropium, which sensitizes bronchial smooth muscle to levodopa-induced constriction; subcutaneous apomorphine is indicated but requires dose reduction to 50% of standard because renal impairment from her diabetes reduces apomorphine clearance.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. Nine months later she requires elective hip arthroplasty for severe osteoarthritis. The orthopedic surgeon's standard perioperative orders include NPO from midnight and hold all non-essential medications. The anesthesiologist asks the movement disorders team for specific perioperative guidance for this patient's levodopa regimen. Which of the following best describes the correct perioperative management strategy for this patient's levodopa and apomorphine, and explains the risk of standard NPO-with-held-medications orders in patients with advanced Parkinson's disease?

• A) All dopaminergic medications should be held from midnight as standard NPO protocol because general anesthesia provides temporary CNS dopamine receptor stimulation through GABA-A receptor modulation, which substitutes for levodopa during the perioperative period; the patient should receive haloperidol 2 mg IV for any agitation during emergence from anesthesia, and levodopa can be resumed with oral intake at 6 to 8 hours postoperatively.
• B) Levodopa should be held 12 hours before surgery to reduce the risk of intraoperative dysrhythmia from peripheral dopamine effects on the cardiac conduction system; a dopamine antagonist drip (metoclopramide 10 mg IV every 6 hours) should be administered throughout the perioperative period to maintain baseline motor tone by blocking D2 autoreceptors and increasing endogenous dopamine synthesis; levodopa is restarted when the patient is taking fluids.
• C) The levodopa regimen should be converted to the controlled-release formulation the night before surgery to take advantage of the 12-hour CR duration of action; a single CR 50/200 mg dose at midnight will maintain therapeutic plasma levodopa concentrations through the surgical procedure, eliminating the need for any intraoperative pharmacological dopaminergic support; postoperatively, the patient returns to her standard IR regimen when oral intake resumes.
• D) Standard NPO-with-held-medications orders are dangerous in patients with advanced Parkinson's disease because abrupt levodopa discontinuation in a patient whose endogenous dopamine synthesis is severely depleted can precipitate an NMS-like syndrome — severe rigidity, hyperthermia, autonomic instability, and altered consciousness — that is potentially life-threatening; the correct perioperative approach is to continue levodopa throughout the perioperative period by alternative routes when the patient is NPO: crushed carbidopa/levodopa tablets administered via nasogastric tube if placed preoperatively, or subcutaneous apomorphine infusion as a bridge; all dopamine-blocking agents including metoclopramide and haloperidol must be avoided; the levodopa regimen should resume as soon as oral intake is possible postoperatively, with no gap in dopaminergic therapy.
• E) The perioperative levodopa management is straightforward because levodopa has a renal elimination half-life of 18 to 24 hours — much longer than the surgical period — so plasma levodopa concentrations will remain therapeutic throughout a procedure lasting up to 8 hours if the last oral dose is taken 2 hours before midnight; the patient will experience mild wearing-off symptoms on emergence but levodopa resumption at the first postoperative meal will fully restore motor function within 30 minutes.

17. [CASE 5 — QUESTION 1] A 76-year-old man with a 12-year history of Parkinson's disease is on carbidopa/levodopa 25/100 mg five times daily, pramipexole 1 mg three times daily, and rasagiline 1 mg daily. His daughter reports that over the past 8 weeks he has developed visual hallucinations — vivid, formed images of small animals in the house — and intermittent paranoid ideation that his home health aide is stealing from him. He has no insight into the abnormal nature of the experiences. His MoCA is 21/30, consistent with mild-to-moderate cognitive impairment. His motor control is adequate. His neurologist first reduces and then discontinues pramipexole, and later tapers rasagiline. Mild motor worsening is managed by modest levodopa increase. The hallucinations and paranoia persist despite these medication reductions. An antipsychotic is now required. Which of the following best identifies the correct antipsychotic choice for PD psychosis in this patient and explains the pharmacological constraint that governs antipsychotic selection in patients with PD?

• A) The pharmacological constraint governing antipsychotic selection in PD is that the agent must not block striatal D2 receptors to a degree that worsens motor function in a patient whose motor benefit depends on dopaminergic D2 receptor stimulation; pimavanserin — a selective inverse agonist at 5-HT2A and 5-HT2C receptors with no dopaminergic receptor activity — is the FDA-approved treatment specifically indicated for hallucinations and delusions associated with Parkinson's disease psychosis and is the preferred agent in this patient; it reduces psychosis without interacting with dopamine receptors and therefore cannot worsen parkinsonism; clozapine is an alternative with robust evidence but requires enrollment in the REMS program for agranulocytosis monitoring with mandatory weekly CBC; quetiapine is widely used off-label with modest evidence and low D2 affinity; risperidone and olanzapine are avoided because their D2 affinity is sufficient to worsen motor function in PD.
• B) The pharmacological constraint in PD psychosis is that all antipsychotics must be given at 25% of their standard psychiatric doses in PD patients because the dopamine-depleted striatum is 4 times more sensitive to D2 blockade than a normal striatum; at 25% of standard dose, any second-generation antipsychotic — including risperidone, olanzapine, and quetiapine — can be safely used; the preferred agent is risperidone 0.25 mg daily because it has the highest 5-HT2A-to-D2 ratio of the available antipsychotics at this dose.
• C) The pharmacological constraint in PD psychosis is that psychosis in PD is entirely caused by serotonergic excess from dopaminergic medications stimulating 5-HT2A receptors in the visual association cortex; therefore only agents with 5-HT2A antagonism are effective; clozapine is the first-line agent because it has the highest 5-HT2A affinity of available antipsychotics; haloperidol is the alternative when clozapine is unavailable because its D2 blockade paradoxically enhances 5-HT2A signaling through a compensatory mechanism.
• D) The correct antipsychotic for PD psychosis is aripiprazole 2 mg daily because aripiprazole's D2 partial agonist properties stabilize dopamine receptor tone — acting as an agonist during off periods when dopamine is low and as an antagonist during on periods when dopamine is high; this self-adjusting pharmacodynamic profile is uniquely suited to the fluctuating dopamine concentrations of PD and provides antipsychotic benefit without motor worsening.
• E) No antipsychotic can be safely used in PD patients with cognitive impairment (MoCA below 26) because all antipsychotics — regardless of receptor profile — carry an FDA black-box warning for increased mortality in elderly patients with dementia-related psychosis; the only safe management in this patient is reducing the levodopa dose below 300 mg daily, which will reduce psychosis by reducing dopaminergic stimulation of the mesolimbic pathway while maintaining some motor benefit from residual endogenous dopamine.

18. [CASE 5 — QUESTION 2] Continuing with the same patient. Pimavanserin is initiated and produces significant improvement in hallucinations and paranoia over 6 weeks. His motor regimen now consists of carbidopa/levodopa 25/100 mg six times daily and selegiline 5 mg twice daily (rasagiline was discontinued; selegiline was added for its symptomatic MAO-B inhibitory benefit). He undergoes a dental procedure and the oral surgeon prescribes meperidine 50 mg every 4 hours as needed for postoperative pain without consulting the neurology team. Four hours after his first meperidine dose he develops agitation, confusion, high fever (39.6°C), diaphoresis, hyperreflexia, bilateral lower limb clonus, and generalized myoclonus. Which of the following best identifies this syndrome, explains the specific pharmacological mechanism, and identifies the opioid analgesics that can be safely used in this patient?

• A) This is an acute dystonic reaction from meperidine's D2 receptor antagonist properties interacting with selegiline; selegiline prevents dopamine catabolism, producing elevated striatal dopamine that is then acutely blocked by meperidine's D2 antagonism, causing the dopaminergic imbalance that produces the acute dystonic posturing; opioids without D2 antagonist properties (morphine, oxycodone) are safe; treatment is benztropine 1 mg IV.
• B) This is neuroleptic malignant syndrome precipitated by meperidine's inhibition of dopamine release from nigrostriatal terminals combined with the high dopamine concentrations maintained by selegiline's MAO-B inhibition; the resulting sudden dopamine depletion at the postsynaptic receptor level produces the NMS triad; treatment is dantrolene and bromocriptine; all opioids are contraindicated with selegiline because all opioids inhibit dopamine release.
• C) This is opioid toxicity from meperidine accumulation caused by selegiline's inhibition of CYP2D6, the enzyme responsible for meperidine's N-demethylation to normeperidine; normeperidine accumulation is the toxic metabolite causing the CNS hyperexcitability; treatment is naloxone; opioids not metabolized by CYP2D6 (fentanyl, methadone) are safe with selegiline.
• D) This is an acute hypertensive crisis caused by meperidine's norepinephrine reuptake inhibitor activity combined with selegiline's prevention of norepinephrine catabolism; the presenting features reflect end-organ damage from severe hypertension; treatment is phentolamine IV; opioids without norepinephrine reuptake inhibitor properties (morphine, oxycodone, hydromorphone) are safe.
• E) This is serotonin syndrome, caused by meperidine's serotonin transporter (SERT) inhibitory properties combined with selegiline's MAO-B inhibition — MAO metabolizes serotonin as well as dopamine, so MAO-B inhibition reduces serotonin catabolism; the combination of impaired serotonin reuptake (meperidine's SERT inhibition) and impaired serotonin catabolism (selegiline's MAO inhibition) produces serotonin accumulation, manifesting as the characteristic triad of altered mental status, autonomic instability, and neuromuscular abnormalities (hyperreflexia, clonus, myoclonus); tramadol is similarly contraindicated because it also inhibits SERT and NET; opioids without serotonergic properties — morphine, oxycodone, hydromorphone, and buprenorphine — are considered safe with MAO-B inhibitors at standard PD doses; treatment is supportive care, removal of offending agents, and cyproheptadine (a 5-HT2A antagonist) for moderate-to-severe cases.

19. [CASE 5 — QUESTION 3] Continuing with the same patient. The serotonin syndrome resolves with discontinuation of meperidine and supportive care. Selegiline is continued. Wearing-off worsens over the following 3 months despite carbidopa/levodopa six times daily with entacapone at each dose. His neurologist considers switching from entacapone to tolcapone for more potent COMT inhibition, explaining that tolcapone also penetrates the CNS and inhibits central COMT — potentially providing additional benefit. Before prescribing, the neurologist obtains baseline liver function tests. ALT is 28 U/L (ULN 40 U/L), AST is 22 U/L (ULN 35 U/L), and total bilirubin is 0.8 mg/dL. Tolcapone 100 mg three times daily is started. At his 8-week scheduled liver function check, ALT is 48 U/L (1.2× ULN). He is asymptomatic — no jaundice, no abdominal discomfort, no fatigue. His motor control has improved substantially on tolcapone. Which of the following correctly identifies the required management action and explains the pharmacological basis for the specific monitoring threshold that governs this decision?

• A) An ALT of 1.2× ULN in an asymptomatic patient with a substantial motor improvement on tolcapone is within an acceptable monitoring range; the tolcapone label specifies discontinuation only if ALT exceeds 3× ULN or is accompanied by symptoms of liver disease; the current result requires no action beyond repeating the LFT at the next scheduled visit in 4 weeks.
• B) An ALT of 1.2× ULN requires reducing the tolcapone dose from 100 mg three times daily to 50 mg three times daily; if ALT normalizes at the lower dose, full-dose therapy can be resumed with biweekly monitoring; this dose-reduction strategy is the preferred initial response to mild transaminase elevation endorsed by the prescribing information.
• C) An ALT of 1.2× ULN is likely caused by tolcapone's inhibition of CYP3A4, which reduces the hepatic clearance of endogenous substrates that are normally cleared by this enzyme; the accumulation of endogenous CYP3A4 substrates in hepatocytes causes the mild transaminase elevation; the management is adding a CYP3A4 inducer (rifampin) to restore normal hepatic clearance while continuing tolcapone.
• D) An ALT of 48 U/L — above the upper limit of normal — mandates immediate tolcapone discontinuation per the FDA prescribing information, which specifies that tolcapone must be stopped if ALT or AST rises above the upper limit of normal on any scheduled or clinical monitoring check; this zero-tolerance threshold for any above-normal result — rather than the 2× or 3× ULN thresholds applied to other hepatotoxic drugs — reflects the three fatal post-marketing cases of fulminant hepatic failure in which early transaminase elevations progressed rapidly to irreversible liver failure in patients who continued tolcapone; the motor improvement achieved with tolcapone, while valuable, does not alter the discontinuation decision.
• E) An ALT of 1.2× ULN in a patient on tolcapone and selegiline is most likely caused by a drug interaction between these two agents — both inhibit MAO-B, and the combination produces additive MAO-B inhibition in hepatocytes that reduces the catabolism of hepatotoxic MAO-B substrates; management is discontinuing selegiline rather than tolcapone, rechecking LFTs in 4 weeks, and continuing tolcapone if the ALT normalizes after selegiline removal.

20. [CASE 5 — QUESTION 4] Continuing with the same patient. Tolcapone is immediately discontinued. ALT normalizes to 26 U/L at the 2-week recheck. His neurologist restarts entacapone 200 mg with each of his six daily carbidopa/levodopa doses to address the wearing-off that returns after tolcapone discontinuation. The patient is also on warfarin for atrial fibrillation, with his INR stable at 2.4 on the most recent check performed 3 weeks ago when he was on tolcapone. The neurologist considers whether the transition from tolcapone to entacapone requires any additional monitoring. Which of the following best explains why the INR requires repeat monitoring after this medication transition and identifies the correct timing?

• A) Repeat INR monitoring is required because tolcapone induces hepatic CYP3A4 expression as a compensatory response to its CYP2C9 inhibition, and the transition from tolcapone to entacapone removes the CYP3A4 induction; without CYP3A4 induction, R-warfarin clearance decreases and the INR rises; INR should be rechecked within 2 to 3 weeks after tolcapone discontinuation to detect this predicted INR increase.
• B) No repeat INR monitoring is required because both tolcapone and entacapone inhibit CYP2C9 through the same catechol ring-mediated mechanism, and the transition between them produces no net change in S-warfarin metabolism; INR can be rechecked at the next routine anticoagulation clinic visit in 4 to 6 weeks.
• C) Repeat INR monitoring is required because both tolcapone and entacapone inhibit CYP2C9 but tolcapone is a more potent CYP2C9 inhibitor than entacapone due to its higher tissue distribution and CNS penetration; removing the stronger inhibitor (tolcapone) and replacing it with the weaker inhibitor (entacapone) is predicted to reduce the degree of CYP2C9 inhibition, decreasing S-warfarin AUC and potentially lowering the INR toward or below therapeutic range; the entacapone prescribing information also specifically recommends INR monitoring when entacapone is added or withdrawn from a warfarin regimen; repeat INR should be checked within 1 to 2 weeks of the transition to detect a potential INR fall.
• D) Repeat INR monitoring is not required because the warfarin INR reflects only the extrinsic coagulation cascade activity, which is not affected by catechol-based COMT inhibitors; the INR change previously documented with entacapone was coincidental and reflected dietary vitamin K variation rather than a pharmacokinetic interaction; COMT inhibitors have no established effect on the warfarin pharmacokinetic pathway.
• E) Repeat INR monitoring is required because entacapone inhibits P-glycoprotein in hepatocyte canalicular membranes, reducing biliary warfarin excretion and causing warfarin accumulation; tolcapone does not inhibit P-glycoprotein because its CNS penetration prevents it from achieving adequate hepatocyte concentrations for P-glycoprotein inhibition; switching from tolcapone to entacapone will therefore raise the INR; recheck within 1 week is needed.

21. [CASE 6 — QUESTION 1] A 50-year-old woman presents to a movement disorders clinic with an 8-year history of Parkinson's disease, diagnosed at age 42. She was initially managed with ropinirole as first-line therapy for 4 years before levodopa was added at age 46 due to inadequate motor control. She has now been on carbidopa/levodopa 25/100 mg four times daily for 4 years and has developed peak-dose dyskinesia affecting 2 to 3 hours of each day. She asks why she was started on ropinirole rather than levodopa at diagnosis, given that levodopa works better, and whether the dyskinesia she now has is a consequence of the levodopa that was eventually added or of the ropinirole she took first. Which of the following most accurately addresses both components of her question — the pharmacological rationale for agonist-first therapy at age 42 and the correct attribution of her current dyskinesia?

• A) The ropinirole-first approach was a mistake — current guidelines recommend levodopa as first-line therapy in all newly diagnosed PD patients regardless of age because the DATATOP trial demonstrated that agonist-first strategies do not reduce long-term dyskinesia risk when the total cumulative levodopa exposure over 10 years is equivalent; her current dyskinesia reflects the 4 years of levodopa she has taken, and the ropinirole contributed nothing to its development.
• B) The ropinirole-first approach was pharmacologically justified at age 42 because her younger age implied a longer anticipated treatment duration — potentially 30 to 40 years — and agonists have a lower intrinsic propensity to induce the striatal maladaptive plasticity that underlies dyskinesia compared with levodopa at equivalent motor control; the strategy aimed to reduce and defer cumulative levodopa exposure, thereby reducing lifetime dyskinesia burden; her current dyskinesia after 4 years of levodopa at age 46 to 50 is correctly attributed to the levodopa, which produces the pulsatile striatal dopamine stimulation that drives the deltaFosB accumulation and AMPA/NMDA receptor sensitization underlying LID — ropinirole does not cause the same degree of striatal sensitization because its longer half-life produces more continuous receptor stimulation; the trade-off of 4 fewer years of levodopa exposure was the intended pharmacological benefit of the agonist-first approach, even though dyskinesia eventually developed after levodopa was added.
• C) The ropinirole-first approach was the correct choice because ropinirole has been definitively shown in randomized controlled trials to prevent levodopa-induced dyskinesia from ever developing — patients who start on ropinirole and later switch to levodopa never develop LID because the D3 receptor sensitization from ropinirole permanently blocks the D1 receptor-mediated direct pathway activation that generates dyskinesia; her current dyskinesia means she must have been non-compliant with ropinirole for a significant period before the switch.
• D) The ropinirole-first approach was chosen because ropinirole has neuroprotective properties that slow dopaminergic neurodegeneration and delay the loss of presynaptic buffering capacity; by preserving more nigrostriatal terminals at the time of levodopa addition, ropinirole pre-treatment was designed to extend the period during which levodopa pharmacokinetic variability is buffered; her early dyskinesia after only 4 years of levodopa confirms that the neuroprotective effect was insufficient and her presynaptic buffer was depleted faster than average.
• E) The ropinirole-first approach was selected because ropinirole selectively stimulates D3 receptors in the dorsal striatum rather than D2 receptors, producing motor benefit through a non-dyskinesiogenic pathway; levodopa-derived dopamine stimulates both D1 and D2 receptors in the dorsal striatum, with D1 stimulation being the sole driver of LID; by pre-exposing her striatum to selective D3 stimulation, the ropinirole primed D3 receptors to competitively inhibit D1-mediated dyskinesia when levodopa was later added; her current dyskinesia reflects the failure of this D3 priming because her disease progression depleted D3-expressing neurons.

22. [CASE 6 — QUESTION 2] Continuing with the same patient. Over the next 3 years, wearing-off and peak-dose dyskinesia become increasingly refractory to oral optimization. At age 53, after extensive multidisciplinary discussion, she undergoes PEG-J placement and begins LCIG infusion. Motor control improves dramatically. At her 18-month LCIG review, routine neurological examination reveals reduced vibration sense in both feet, absent ankle reflexes bilaterally, and mild distal toe extensor weakness — findings absent at her 12-month review. Nerve conduction studies confirm a length-dependent axonal sensorimotor peripheral neuropathy. Her neurologist orders plasma PLP (pyridoxal-5'-phosphate), homocysteine, methylmalonic acid (MMA), B12, and folate levels. Results: PLP 12 nmol/L (reference 20 to 90 nmol/L — low), homocysteine 28 micromol/L (reference less than 15 — elevated), MMA 0.38 micromol/L (borderline), B12 280 pg/mL (normal), folate 6.2 ng/mL (normal). Which of the following best explains the mechanism of this neuropathy and the significance of the biochemical pattern?

• A) The low PLP and elevated homocysteine in this patient on LCIG reflect carbidopa-mediated PLP depletion: carbidopa inhibits AADC by forming a covalent bond with the PLP cofactor at the enzyme active site, sequestering PLP from the available systemic pool; at the high continuous carbidopa doses delivered by LCIG infusion (typically substantially exceeding the 75 to 100 mg daily of oral therapy), systemic PLP depletion can become clinically significant; PLP is required as a cofactor for multiple enzymes in the methionine-homocysteine cycle including cystathionine beta-synthase and others involved in one-carbon metabolism; PLP deficiency impairs these pathways, causing homocysteine accumulation; elevated homocysteine is itself a risk factor for axonal neuropathy through oxidative endothelial injury and direct neuronal toxicity; the combination of low PLP (direct nutritional-functional deficiency impairing myelin-related enzyme pathways) and elevated homocysteine (independent pro-neuropathic mechanism) provides the mechanistic substrate for the observed axonal neuropathy; B12 and folate are normal, confirming that the homocysteine elevation is driven by PLP-dependent remethylation impairment rather than B12 or folate deficiency.
• B) The neuropathy reflects progressive autonomic neuropathy from PD itself spreading to sensorimotor fibers as disease advances; the low PLP is a consequence of the neuropathy rather than a cause — damaged peripheral axons cannot transport PLP retrogradely to the neuronal cell body, causing distal PLP depletion; the elevated homocysteine reflects hepatic dysfunction from LCIG-associated peritonitis episodes; no pharmacological intervention is required; LCIG should be continued because its motor benefits outweigh the disease-progression neuropathy.
• C) The neuropathy is caused by levodopa's direct axonal toxicity through reactive oxygen species generated by catechol auto-oxidation; at the continuous plasma levodopa concentrations maintained by LCIG (typically 3 to 5 micromol/L), levodopa undergoes spontaneous oxidation to dopamine quinones that penetrate peripheral nerve axonal membranes and inhibit mitochondrial complex I; the low PLP is an unrelated nutritional finding; management is antioxidant supplementation with alpha-lipoic acid and N-acetylcysteine while continuing LCIG.
• D) The neuropathy and biochemical pattern reflect folate deficiency misidentified by the laboratory — the reported folate level of 6.2 ng/mL is actually below the laboratory-specific reference range for patients on LCIG; LCIG significantly increases folate requirements because levodopa competes with folate for DHFR-mediated methylation; the low PLP and elevated homocysteine are secondary to folate deficiency; management is high-dose folate supplementation (5 mg daily) without any change to the carbidopa or levodopa regimen.
• E) The neuropathy is caused by direct jejunal mucosal damage from the LCIG cassette's low pH (the carbidopa/levodopa gel is buffered at pH 3.8 to prevent levodopa oxidation), which produces chronic jejunal acidosis that impairs B12 absorption through the distal ileum; the resulting B12 deficiency produces the subacute combined degeneration pattern; the laboratory measurement of B12 is falsely normal because LCIG gel directly interferes with the intrinsic factor-mediated B12 assay used by the laboratory; the management is monthly cyanocobalamin 1000 mcg IM injection.

23. [CASE 6 — QUESTION 3] Continuing with the same patient. Pyridoxine supplementation (50 mg daily), folate (1 mg daily), and LCIG infusion rate reduction are implemented. At her 6-month neuropathy follow-up, nerve conduction studies show no progression of the neuropathy. However, at her 24-month LCIG review, despite supplementation and rate reduction, repeat NCS confirms mild but definite neuropathy progression — distal sensory loss has extended slightly more proximally and the amplitude of sural nerve action potentials has reduced by 20%. Her movement disorders neurologist and neurophysiologist discuss the risk-benefit picture: LCIG is providing excellent motor control (less than 30 minutes daily off time), but the neuropathy appears to be slowly progressing despite the mitigation measures. Deep brain stimulation is raised as an alternative. She has MoCA 27/30, no significant surgical comorbidities, and good levodopa responsiveness. Which of the following best identifies the key advantage of DBS over LCIG specifically relevant to this patient's current situation, and correctly describes the mechanism by which DBS achieves motor benefit?

• A) DBS is preferred over LCIG in this patient specifically because DBS provides superior long-term motor control to LCIG in all patients with advanced PD, and the 5-year motor outcomes data from the INVEST-PD trial consistently show better UPDRS scores at 5 years with STN-DBS than with LCIG regardless of neuropathy; the mechanism of DBS is postsynaptic D2 receptor reactivation through the application of high-frequency electrical fields that directly stimulate dopamine receptor conformational changes.
• B) DBS is preferred because LCIG requires continuous jejunal carbidopa delivery and carbidopa is the neurotoxic agent responsible for the neuropathy; DBS eliminates the need for carbidopa entirely because it bypasses dopaminergic receptor signaling through direct glutamate receptor modulation in the thalamus; patients who transition from LCIG to DBS typically discontinue all dopaminergic medications because DBS replaces rather than supplements dopaminergic therapy.
• C) DBS is preferred because LCIG-associated neuropathy is caused by excessive levodopa plasma concentrations producing peripheral nerve mitochondrial complex I inhibition; DBS allows complete levodopa cessation, removing the neurotoxic plasma levodopa; patients who transition from LCIG to DBS can eliminate levodopa from their regimen within 6 months of DBS activation.
• D) DBS is preferred because LCIG delivers continuous levodopa which maintains chronically elevated plasma 3-OMD levels from continuous COMT activity; the elevated 3-OMD permeates the perineurium and competitively inhibits PLP-dependent enzymes in peripheral Schwann cells; DBS allows LCIG discontinuation, removing the 3-OMD source and allowing Schwann cell remyelination to proceed.
• E) DBS of the subthalamic nucleus is specifically advantageous for this patient because it achieves motor benefit through high-frequency neuromodulation of basal ganglia circuitry — suppressing the pathologically hyperactive STN output to the GPi and restoring more physiological thalamo-cortical motor signaling — without requiring continuous high-dose carbidopa delivery; after STN-DBS, levodopa doses can typically be reduced by 50 to 60%, which reduces LCIG infusion rates and carbidopa exposure substantially or allows LCIG discontinuation entirely; this reduction in carbidopa dose removes the primary driver of PLP depletion and should arrest or potentially allow partial recovery of the neuropathy — making DBS the preferred advanced therapy in a patient whose LCIG-associated neuropathy is progressing despite mitigation measures.

24. [CASE 6 — QUESTION 4] Continuing with the same patient. She agrees to DBS evaluation and is referred to the neurosurgical team. While awaiting the surgical assessment, her 22-year-old daughter, who is a first-year medical student, accompanies her to the clinic appointment. The daughter asks the neurologist directly: "If my mother had been started on levodopa at age 42 instead of ropinirole, how much earlier or worse would her dyskinesia have been? And what is her dyskinesia risk from here forward?" The neurologist uses this as a teaching moment to address the epidemiology of levodopa-induced dyskinesia and to explain how cumulative exposure time determines the population-level risk. Which of the following most accurately characterizes the published epidemiology of levodopa-induced dyskinesia prevalence by years of treatment and correctly explains the impact of earlier versus later levodopa initiation on the dyskinesia timeline?

• A) The published dyskinesia prevalence data show that LID develops in fewer than 5% of patients after 10 years of levodopa treatment at standard doses; the majority of LID cases occur only in patients who require doses above 800 mg daily, reflecting a threshold-dependent rather than duration-dependent mechanism; earlier levodopa initiation at age 42 instead of 46 would have had negligible impact on her dyskinesia risk because neither dose nor duration is the primary determinant — genetic factors account for over 90% of LID risk.
• B) The published dyskinesia prevalence data are highly variable — ranging from 5% to 95% at 5 years depending on the population studied — and cannot be reliably quoted to patients as predictive of individual risk; the risk in young-onset PD is entirely dominated by the COMT Val158Met genotype, which should be tested before starting levodopa in any patient under 55 to provide personalized dyskinesia risk counseling.
• C) The published data show that LID prevalence reaches a plateau of approximately 25 to 30% by 5 years of levodopa treatment and does not increase substantially beyond this, because the striatal maladaptive plasticity underlying LID reaches its maximum possible degree of sensitization within 5 years regardless of further exposure; earlier levodopa initiation therefore only affects whether dyskinesia develops within the first 5 years and has no impact on dyskinesia risk beyond that plateau.
• D) The published literature consistently reports levodopa-induced dyskinesia prevalence of approximately 30% after 3 years of treatment, over 50% after 5 years, and approaching 90% after 10 years in most series, with younger age at diagnosis associated with faster sensitization; had her levodopa been started at age 42 rather than 46, those 4 additional years of pulsatile levodopa stimulation would have begun the sensitization process earlier — placing her 4 years further along the dyskinesia trajectory at any given current age; the agonist-first strategy deferred the onset of levodopa-driven sensitization by 4 years, and while dyskinesia still developed after levodopa was added, its onset was shifted later on her personal timeline; from here forward, her dyskinesia risk continues to accumulate as long as levodopa is maintained — at 4 years of levodopa exposure she is already past the 50% prevalence point — but the DBS being considered will allow a 50 to 60% levodopa dose reduction, which reduces the sensitization increment per year and may slow further dyskinesia progression.
• E) The epidemiology of LID is straightforward and dose-dependent: dyskinesia prevalence is directly proportional to total daily levodopa dose, with a threshold of 400 mg daily below which dyskinesia never occurs; every 100 mg increment above 400 mg increases dyskinesia prevalence by approximately 15% per year; at her current dose of 400 mg daily she is at the threshold and has a 0% annual increment; had she been started on levodopa at age 42 at the standard starting dose of 300 mg daily, she would never have developed dyskinesia because 300 mg is below the dyskinesia threshold.